Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 2/2007

01-04-2007 | Review

Bone morphogenetic proteins in destructive and remodeling arthritis

Authors: Rik JU Lories, Frank P Luyten

Published in: Arthritis Research & Therapy | Issue 2/2007

Login to get access

Abstract

Joint destruction and tissue responses determine the outcome of chronic arthritis. Joint inflammation and damage are often the dominant clinical presentation. However, in some arthritic diseases, in particular the spondyloarthritides, joint remodeling is a prominent feature, with new cartilage and bone formation leading to ankylosis and contributing to loss of function. A role for bone morphogenetic proteins in joint remodeling has been demonstrated in the formation of both enthesophytes and osteophytes. Data from genetic models support a role for bone morphogenetic protein signaling in cartilage homeostasis. Finally, this signaling pathway is likely to play a steering role in the synovium.
Appendix
Available only for authorised users
Literature
1.
McInnes IB, Liew FY: Cytokine networks – towards new therapies for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2005, 1: 31-39. 10.1038/ncprheum0020.CrossRefPubMed
2.
Sato K, Takayanagi H: Osteoclasts, rheumatoid arthritis, and osteoimmunology. Curr Opin Rheumatol. 2006, 18: 419-426. 10.1097/01.bor.0000231912.24740.a5.CrossRefPubMed
3.
Karouzakis E, Neidhart M, Gay RE, Gay S: Molecular and cellular basis of rheumatoid joint destruction. Immunol Lett. 2006, 106: 8-13. 10.1016/j.imlet.2006.04.011.CrossRefPubMed
4.
Luyten FP, Lories RJ, Verschueren P, De Vlam K, Westhovens R: Contemporary concepts of inflammation, damage and repair in rheumatic diseases. Best Pract Res Clin Rheumatol. 2006, 20: 829-848. 10.1016/j.berh.2006.06.009.CrossRefPubMed
5.
Buckwalter JA: Articular cartilage injuries. Clin Orthop. 2002, 402: 21-37. 10.1097/00003086-200209000-00004.CrossRefPubMed
6.
Rau R: Is remission in rheumatoid arthritis associated with radiographic healing?. Clin Exp Rheumatol. 2006, 24: S041-S044.
7.
De Vlam K, Lories RJ, Luyten FP: Mechanisms of pathologic new bone formation. Curr Rheumatol Rep. 2006, 8: 332-337.CrossRefPubMed
8.
Lories RJ, Luyten FP: Bone morphogenetic protein signaling in joint homeostasis and disease. Cytokine Growth Factor Rev. 2005, 16: 287-298. 10.1016/j.cytogfr.2005.02.009.CrossRefPubMed
9.
Lories RJU, Derese I, Ceuppens JL, Luyten FP: Bone morphogenetic proteins 2 and 6, expressed in arthritic synovium, are regulated by proinflammatory cytokines and differentially modulate fibroblast-like synoviocyte apoptosis. Arthritis Rheum. 2003, 48: 2807-2818. 10.1002/art.11389.CrossRefPubMed
10.
Miyazono K, Maeda S, Imamura T: BMP receptor signaling: transcriptional targets, regulation of signals, and signaling crosstalk. Cytokine Growth Factor Rev. 2005, 16: 251-263. 10.1016/j.cytogfr.2005.01.009.CrossRefPubMed
11.
Urist MR: Bone: formation by autoinduction. Science. 1965, 150: 893-899. 10.1126/science.150.3698.893.CrossRefPubMed
12.
Kronenberg HM: Developmental regulation of the growth plate. Nature. 2003, 423: 332-336. 10.1038/nature01657.CrossRefPubMed
13.
Luyten FP, Lories RJ, De Bari C, De Valck D, Dell'Accio F: Bone morphogenetic proteins and the synovial joint. Bone Morphogenetic Proteins: fRegeneration of Bone and Beyond. Edited by: Vukicevic S, Sampath KT. 2004, Basel: Birckhäuser AG, 187-212.CrossRef
14.
Martinovic S, Borovecki F, Sampath KT, Vukicevic S: Biology of bone morphogenetic proteins. Bone Morphogenetic Proteins: Regeneration of Bone and Beyond. Edited by: Vukicevic S, Sampath KT. 2004, Basel: Birckhäuser AG, 45-72.CrossRef
15.
Balemans W, Van Hul W: Extracellular regulation of BMP signaling in vertebrates: a cocktail of modulators. Dev Biol. 2002, 250: 231-250.CrossRefPubMed
16.
Hoffmann A, Preobrazhenska O, Wodarczyk C, Medler Y, Winkel A, Shahab S, Huylebroeck D, Gross G, Verschueren K: Transforming growth factor-beta-activated kinase-1 (TAK1), a MAP3K, interacts with Smad proteins and interferes with osteogenesis in murine mesenchymal progenitors. J Biol Chem. 2005, 280: 27271-27283. 10.1074/jbc.M503368200.CrossRefPubMed
17.
Lories RJU, Derese I, Luyten FP: Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest. 2005, 115: 1571-1579. 10.1172/JCI23738.PubMedCentralCrossRefPubMed
18.
Lories RJ, Daans M, Matthys P, Kasran A, Tylzanowski P, Ceuppens JL, Luyten FP: Noggin haploinsufficiency differentially affects tissue responses in destructive and remodeling arthritis. Arthritis Rheum. 2006, 54: 1736-1746. 10.1002/art.21897.CrossRefPubMed
19.
Lories RJ, Matthys P, Derese I, De Vlam K, Luyten FP: Ankylosing enthesitis, dactylitis and onychoperiostitis in a mouse model of psoriatic arthritis. Ann Rheum Dis. 2004, 63: 595-598. 10.1136/ard.2003.013599.PubMedCentralCrossRefPubMed
20.
Holmdahl R, Jansson L, Andersson M, Jonsson R: Genetic, hormonal and behavioural influence on spontaneously developing arthritis in normal mice. Clin Exp Immunol. 1992, 88: 467-472.PubMedCentralCrossRefPubMed
21.
Matthys P, Lories RJ, De Klerck B, Heremans H, Luyten FP, Billiau M: Dependence on interferon-gamma for the spontaneous occurrence of arthritis in DBA/1 mice. Arthritis Rheum. 2003, 48: 2983-2988. 10.1002/art.11273.CrossRefPubMed
22.
Glansbeek HL, van Beuningen HM, Vitters EL, Morris EA, van der Kraan PM, van den Berg WB: Bone morphogenetic protein 2 stimulates articular cartilage proteoglycan synthesis in vivo but does not counteract interleukin-1alpha effects on proteoglycan synthesis and content. Arthritis Rheum. 1997, 40: 1020-1028. 10.1002/art.1780400605.CrossRefPubMed
23.
van Beuningen HM, Glansbeek HL, van der Kraan PM, van den Berg WB: Differential effects of local application of BMP-2 or TGF-beta 1 on both articular cartilage composition and osteophyte formation. Osteoarthritis Cartilage. 1998, 6: 306-317. 10.1053/joca.1998.0129.CrossRefPubMed
24.
van Lent PL, Blom AB, van der KP, Holthuysen AE, Vitters E, van Rooijen N, Smeets RL, Nabbe KC, van den Berg WB: Crucial role of synovial lining macrophages in the promotion of transforming growth factor beta-mediated osteophyte formation. Arthritis Rheum. 2004, 50: 103-111. 10.1002/art.11422.CrossRefPubMed
25.
Blom AB, van Lent PL, Holthuysen AE, van der Kraan PM, Roth J, van Rooijen N, van den Berg WB: Synovial lining macrophages mediate osteophyte formation during experimental osteoarthritis. Osteoarthritis Cartilage. 2004, 12: 627-635. 10.1016/j.joca.2004.03.003.CrossRefPubMed
26.
Scharstuhl A, Vitters EL, van der Kraan PM, van den Berg WB: Reduction of osteophyte formation and synovial thickening by adenoviral overexpression of transforming growth factor beta/bone morphogenetic protein inhibitors during experimental osteoarthritis. Arthritis Rheum. 2003, 48: 3442-3451. 10.1002/art.11328.CrossRefPubMed
27.
Blaney Davidson EN, Vitters EL, van der Kraan PM, van den Berg WB: Expression of transforming growth factor-beta (TGFbeta) and the TGFbeta signalling molecule SMAD-2P in spontaneous and instability-induced osteoarthritis: role in cartilage degradation, chondrogenesis and osteophyte formation. Ann Rheum Dis. 2006, 65: 1414-1421. 10.1136/ard.2005.045971.CrossRefPubMed
28.
Zoricic S, Maric I, Bobinac D, Vukicevic S: Expression of bone morphogenetic proteins and cartilage-derived morphogenetic proteins during osteophyte formation in humans. J Anat. 2003, 202: 269-277.PubMedCentralCrossRefPubMed
29.
Nakase T, Miyaji T, Tomita T, Kaneko M, Kuriyama K, Myoui A, Sugamoto K, Ochi T, Yoshikawa H: Localization of bone morphogenetic protein-2 in human osteoarthritic cartilage and osteophyte. Osteoarthritis Cartilage. 2003, 11: 278-284. 10.1016/S1063-4584(03)00004-9.CrossRefPubMed
30.
McGonagle D, Gibbon W, Emery P: Classification of inflammatory arthritis by enthesitis. Lancet. 1998, 352: 1137-1140. 10.1016/S0140-6736(97)12004-9.CrossRefPubMed
31.
Francois RJ, Braun J, Khan MA: Entheses and enthesitis: a histopathologic review and relevance to spondyloarthritides. Curr Opin Rheumatol. 2001, 13: 255-264. 10.1097/00002281-200107000-00003.CrossRefPubMed
32.
Moskowitz RW: Bone remodeling in osteoarthritis: subchondral and osteophytic responses. Osteoarthritis Cartilage. 1999, 7: 323-324. 10.1053/joca.1998.0181.CrossRefPubMed
33.
Menkes CJ, Lane NE: Are osteophytes good or bad?. Osteoarthritis Cartilage. 2004, 12 (Suppl A): S53-S54. 10.1016/j.joca.2003.09.003.CrossRefPubMed
34.
Lories RJ, Derese I, De Bari C, Luyten FP: Evidence for uncoupling of inflammation and joint remodeling in a mouse model of Spondyloarthritis. Arthritis Rheum. 2007, 56: 489-497. 10.1002/art.22372.CrossRefPubMed
35.
Rountree RB, Schoor M, Chen H, Marks ME, Harley V, Mishina Y, Kingsley DM: BMP receptor signaling is required for postnatal maintenance of articular cartilage. PLoS Biol. 2004, 2: e355-10.1371/journal.pbio.0020355.PubMedCentralCrossRefPubMed
36.
van der Kraan PM, Vitters EL, van Beuningen HM, van de Loo FA, van den Berg WB: Role of nitric oxide in the inhibition of BMP-2-mediated stimulation of proteoglycan synthesis in articular cartilage. Osteoarthritis Cartilage. 2000, 8: 82-86. 10.1053/joca.1999.0275.CrossRefPubMed
37.
Luyten FP: Mesenchymal stem cells in arthritis. Rheumatoid Arthritis: Frontiers in Pathofysiology and Treatment. Edited by: Panayi GS, Firestein GS, Wollheim FA. 2005, Oxford: Oxford University Press, 551-559.
38.
Marinova-Mutafchieva L, Taylor P, Funa K, Maini RN, Zvaifler NJ: Mesenchymal cells expressing bone morphogenetic protein receptors are present in the rheumatoid arthritis joint. Arthritis Rheum. 2000, 43: 2046-2055. 10.1002/1529-0131(200009)43:9<2046::AID-ANR16>3.0.CO;2-8.CrossRefPubMed
39.
Marinova-Mutafchieva L, Williams RO, Funa K, Maini RN, Zvaifler NJ: Inflammation is preceded by tumor necrosis factor-dependent infiltration of mesenchymal cells in experimental arthritis. Arthritis Rheum. 2002, 46: 507-513. 10.1002/art.10126.CrossRefPubMed
40.
Sen M: Wnt signalling in rheumatoid arthritis. Rheumatology (Oxford). 2005, 44: 708-713. 10.1093/rheumatology/keh553.CrossRef
41.
Bramlage CP, Haupl T, Kaps C, Ungethum U, Krenn V, Pruss A, Muller GA, Strutz F, Burmester GR: Decrease in expression of bone morphogenetic proteins 4 and 5 in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther. 2006, 8: R58-10.1186/ar1923.PubMedCentralCrossRefPubMed
42.
De Bari C, Dell'Accio F, Tylzanowski P, Luyten FP: Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum. 2001, 44: 1928-1942. 10.1002/1529-0131(200108)44:8<1928::AID-ART331>3.0.CO;2-P.CrossRefPubMed
43.
Steenvoorden MM, Tolboom TC, van der PG, Lowik C, Visser CP, Degroot J, Gittenberger-Degroot AC, Deruiter MC, Wisse BJ, Huizinga TW, et al: Transition of healthy to diseased synovial tissue in rheumatoid arthritis is associated with gain of mesenchymal/fibrotic characteristics. Arthritis Res Ther. 2006, 8: R165-10.1186/ar2073.PubMedCentralCrossRefPubMed
44.
Filer A, Pitzalis C, Buckley CD: Targeting the stromal microenvironment in chronic inflammation. Curr Opin Pharmacol. 2006, 6: 393-400. 10.1016/j.coph.2006.03.007.PubMedCentralCrossRefPubMed
45.
Muller-Ladner U, Kriegsmann J, Franklin BN, Matsumoto S, Geiler T, Gay RE, Gay S: Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol. 1996, 149: 1607-1615.PubMedCentralPubMed
46.
Yamanishi Y, Boyle DL, Pinkoski MJ, Mahboubi A, Lin T, Han Z, Zvaifler NJ, Green DR, Firestein GS: Regulation of joint destruction and inflammation by p53 in collagen-induced arthritis. Am J Pathol. 2002, 160: 123-130.PubMedCentralCrossRefPubMed
47.
48.
49.
Buckley CD, Filer A, Haworth O, Parsonage G, Salmon M: Defining a role for fibroblasts in the persistence of chronic inflammatory joint disease. Ann Rheum Dis. 2004, 63 (Suppl 2): ii92-ii95. 10.1136/ard.2004.028332.PubMedCentralPubMed
Metadata
Title
Bone morphogenetic proteins in destructive and remodeling arthritis
Authors
Rik JU Lories
Frank P Luyten
Publication date
01-04-2007
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 2/2007
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar2135

Other articles of this Issue 2/2007

Arthritis Research & Therapy 2/2007 Go to the issue

Review

Immune mechanisms in the pathogenesis of idiopathic inflammatory myopathies

Research article

Association of the diplotype configuration at the N-acetyltransferase 2 gene with adverse events with co-trimoxazole in Japanese patients with systemic lupus erythematosus

Review

Cells of the synovium in rheumatoid arthritis. B cells

Research article

Differential expression of RANK, RANK-L, and osteoprotegerin by synovial fluid neutrophils from patients with rheumatoid arthritis and by healthy human blood neutrophils

Research article

A new classification of HLA-DRB1 alleles differentiates predisposing and protective alleles for autoantibody production in rheumatoid arthritis

Commentary

T cells and post menopausal osteoporosis in murine models
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits